Scholarlink

<p>Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Allison Makovec,
  • Ella Boytim,
  • Ava Gustafson,
  • Megan Ludwig,
  • Liangjun Wang,
  • Atef Ali,
  • Khalid Ishani,
  • Christine Luo,
  • Hannah E. Bergom,
  • Emily John,
  • Sydney Tape,
  • Samuel Kellen,
  • Aiden Deacon,
  • Fatemah Iman Dewji,
  • Camden Richter,
  • Lauren Cookle,
  • David Moline,
  • Jonathan P. Rennhack,
  • Justin M. Drake,
  • Emmanuel S. Antonarakis,
  • David A. Largaespada,
  • Julie H. Ostrander,
  • Justin Hwang

摘要

Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.